Patient characteristics
| Patient characteristics,*n = 21 . | No. (%) or median (range) . |
|---|---|
| Age, y | 59 (19-75) |
| Time from primary diagnosis | |
| Primary rel/ref <12 mo | 17 (81) |
| Relapse >12 mo | 4 (19) |
| Karnofsky performance status | |
| ≥90 | 12 (57) |
| <90 | 9 (43) |
| Elevated LDH | 8 (38) |
| Stage | |
| I/II | 10 (48) |
| III/IV | 11 (52) |
| Histology | |
| De novo DLBCL | 12 (57) |
| GC | 3 (14) |
| Non-GC | 9 (43) |
| PMBL | 4 (19) |
| Richter transformation | 5 (24) |
| Secondary age-adjusted IPI | |
| Low/low-intermediate, 0-1 | 13 (62) |
| High-intermediate/high, 2-3 | 8 (38) |
| Patient characteristics,*n = 21 . | No. (%) or median (range) . |
|---|---|
| Age, y | 59 (19-75) |
| Time from primary diagnosis | |
| Primary rel/ref <12 mo | 17 (81) |
| Relapse >12 mo | 4 (19) |
| Karnofsky performance status | |
| ≥90 | 12 (57) |
| <90 | 9 (43) |
| Elevated LDH | 8 (38) |
| Stage | |
| I/II | 10 (48) |
| III/IV | 11 (52) |
| Histology | |
| De novo DLBCL | 12 (57) |
| GC | 3 (14) |
| Non-GC | 9 (43) |
| PMBL | 4 (19) |
| Richter transformation | 5 (24) |
| Secondary age-adjusted IPI | |
| Low/low-intermediate, 0-1 | 13 (62) |
| High-intermediate/high, 2-3 | 8 (38) |
CR, complete remission; FDG-PET, fluorodeoxyglucose–positron emission tomography; IPI, International Prognostic Index; LDH, lactate dehydrogenase; ORR, overall response rate; PMBL, primary mediastinal large B-cell lymphoma; PR, partial remission.
Patient characteristics of 21 patients with relapsed or primary refractory DLBCL before ibrutinib with R-ICE treatment.